全部商品分类
.jpg)
1/2
用小程序，查商品更便捷
产品介绍
产品介绍
产品信息
抗原名称
JAK2 (V617F),JAK2,JAK2 ,FLT3,JAK1,,
商品描述
LY2784544是一种有效的JAK2抑制剂，IC50为3 nM，作用于JAK2V617F有效，比作用于JAK1和JAK3选择性高8和20倍。LY2784544也抑制IL-3激活的野生型JAK2，IC50为2.26 µM。在增殖实验中，LY2784544 作用于JAK2 V617F驱动的细胞中，具有抗增殖活性，IC50为 68 nM,而作用于野生型JAK2驱动的细胞时，IC50为1356 nM，作用于JAK3驱动的细胞时，IC50为940 nM。
分子量
469.94
纯度
>98%
可溶性
Ethanol ：9 mg/mL (19.15 mM)
DMSO ：87 mg/mL (185.1 mM)
DMSO ：87 mg/mL (185.1 mM)
外观
白色粉末
In vitro(体外研究)
LY2784544 also inhibits IL-3-activated wild type JAK2 with IC50 of 2.26 μM. Similarly in the proliferation assay, LY2784544 shows antiproliferation activity in JAK2 V617F-driven cells with IC50 of 68 nM, compared to 1.36 μM in wild type JAK2-driven cells and 0.94 μM in JAK3-driven cells. Though biochemical assays do not reveal selectivity of LY2784544 for mutant JAK2V617F, LY2784544 shows higher selectivity for inhibition of JAK2-mediated signaling and induction of apoptosis in Ba/F3 cells expressing JAK2V617F than wild-type cells.
In vivo(体内研究)
LY2784544 significantly inhibits STAT5 phosphorylation in Ba/F3-JAK2 V617F-GFP xenografts with a Threshold Effective Dose 50 (TED50) of 12.7 mg/kg. LY2784544 also reduces Ba/F3-JAK2 V617F-GFP tumor burden in the JAK2 V617F-induced MPN model with a TED50 of 13.7 mg/kg after oral treatment. LY2784544 has no effect on CD71/Ter119 positive erythroid progenitors in spleens of SCID mice after oral treatment.
背景
别名
gandotinib
分子式
C23H25ClFN7O
CAS号
1229236-86-5
制备和贮存
保存方式
Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.
声明 ：本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。